{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-208059","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.816230+00:00","generated_at":"2026-06-11T20:55:03.929933+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru Q3 net income $6.3M on ENTADFI gain; pipeline updates for enobosarm, sabizabulin","bullets":["Net income $6.3M ($0.07/diluted share) vs net loss $22.2M ($0.28) in Q3 2022; revenue $3.3M down from $9.6M.","Cash burn reduced to $7.3M in Q3, down $16.1M from prior quarter; cash $16.2M at June 30, 2023.","Sold ENTADFI for $20M in April 2023; potential $80M in sales milestones. Gain of $17.5M recognized.","FDA agrees on Phase 3 ENABLAR-2 design; ORR endpoint in Stage 1 may support accelerated approval for enobosarm in metastatic breast cancer.","Plans to expand sabizabulin Phase 3 confirmatory study to all viral lung infections; FDA meeting scheduled for September 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-208059","json":"https://secwatch.observer/filing/0001193125-23-208059.json","markdown":"https://secwatch.observer/filing/0001193125-23-208059.md","text":"https://secwatch.observer/filing/0001193125-23-208059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312523208059/0001193125-23-208059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312523208059/d463183d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:55:03.929933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d1373fad223dd4b16dc07d2ea9dbd5e2f7cd9ff","claim":"VERU INC. reported financial results for the quarter and nine months ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Veru Inc. issued a press release (the “Press Release”) announcing results for the quarter and nine months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312523208059/0001193125-23-208059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and nine months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}